摘要目前，多系统萎缩的临床治疗仍以对症治疗为主。虽然现有药物可部分缓解患者的运动症状和自主神经功能障碍，但总体疗效不尽如人意，且缺乏有效的疾病修饰治疗方法。近年来，随着对于疾病机制认识的不断加深，靶向关键致病因子α-突触核蛋白的治疗方法逐渐成为本病治疗领域关注的焦点。文中重点聚焦靶向免疫疗法，就国内外最新研究进展进行综述，旨在为多系统萎缩新型治疗策略的开发提供理论参考。

abstractsCurrently, the clinical management of multiple system atrophy (MSA) is primarily limited to symptomatic treatment. While existing medications can partially alleviate motor symptoms and autonomic dysfunction, their overall efficacy remains unsatisfactory, and there is a lack of effective disease-modifying therapies. In recent years, with the deepening understanding of disease mechanisms, alpha-synuclein, identified as a key pathogenic factor, has become a major target in MSA therapeutic research. This article concentrates on targeted immunotherapy and reviews recent global and domestic advances, aiming to provide a theoretical reference for the development of novel therapeutic strategies for MSA.